Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD

Blood (2019) 134 (Supplement_1): 230.

https://doi.org/10.1182/blood-2019-126262

Published: 2019

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

Using Data Visualization to Support the Need for Chronic Lymphocytic Leukemia Provider Education

Janelle Schrag, MPH, Ellen Kendall, Monique D. Dawkins, EdD, Leigh Boehmer, PharmD, Brian Koffman, MDM, DCFP, DABFM, MSEd

Blood (2019) 134 (Supplement_1): 5827.

https://doi.org/10.1182/blood-2019-128710

Published: 2019

Journal Articles

The Impact of Hematopoietic Stem Cell Transplantation on Work and Productivity Loss in Patients with Acute Leukemia: Results from a Rapid Review

Tayler Scory, MSc, Eileen Shaw, MSc, Tara Cowling, MSc, Francois Peloquin, MSc, Verna L Welch, PhD MPH, Majed Charaan, MSc, MBA, Andrew Brown, PhD

Blood (2019) 134 (Supplement_1): 5829.

https://doi.org/10.1182/blood-2019-121814

Published: 2019

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

Journal Articles

Effect of Age on Healthcare Utilization in Patients with Sickle Cell

Nicholas Hamilton, Payal Desai, MD, Nita Williams, Mikaela D. Moore, BS, Andrew I. Schamess, MD

Blood (2019) 134 (Supplement_1): 1019.

https://doi.org/10.1182/blood-2019-127543

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Oliver Lomas, MD DPhil, MRCP, Sarah Gooding, MD PhD, Karthik Ramasamy, MD PhD, Angela Hamblin, MD PhD, Maite Cabes, PhD, Helene Marie-Pierre Dreau, PhD, Edward Wilson, FRCPath, MRCP

Blood (2019) 134 (Supplement_1): 3062.

https://doi.org/10.1182/blood-2019-125145

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

Xueyan Chen, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2692.

https://doi.org/10.1182/blood-2019-124977

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Ellen Cusano, Adrienne Lee, MD, Julia Hews-Girard, RN BScN MN

Blood (2019) 134 (Supplement_1): 2399.

https://doi.org/10.1182/blood-2019-129665

Published: 2019

Journal Articles

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Arash Mahajerin, MD MS, Anisha M. Patel, PhD, Erru Yang, MS, Chinelo C. Orji, MS, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 2398.

https://doi.org/10.1182/blood-2019-123713

Published: 2019

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

https://doi.org/10.1182/blood-2019-130990

Published: 2019

NARROW

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Using Data Visualization to Support the Need for Chronic Lymphocytic Leukemia Provider Education

The Impact of Hematopoietic Stem Cell Transplantation on Work and Productivity Loss in Patients with Acute Leukemia: Results from a Rapid Review

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Effect of Age on Healthcare Utilization in Patients with Sickle Cell

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only